Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine
Status:
Recruiting
Trial end date:
2025-12-14
Target enrollment:
Participant gender:
Summary
This study will evaluate the efficacy and safety of erenumab in migraine prevention in
children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study
hypothesis is that in pediatric subjects with episodic migraine, the combined erenumab dose
group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly
migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).